IL203130A - Variants of 44 cd splicing products for the diagnosis and treatment of neurodegenerative diseases - Google Patents
Variants of 44 cd splicing products for the diagnosis and treatment of neurodegenerative diseasesInfo
- Publication number
- IL203130A IL203130A IL203130A IL20313010A IL203130A IL 203130 A IL203130 A IL 203130A IL 203130 A IL203130 A IL 203130A IL 20313010 A IL20313010 A IL 20313010A IL 203130 A IL203130 A IL 203130A
- Authority
- IL
- Israel
- Prior art keywords
- diagnosis
- treatment
- neurodegenerative diseases
- splice variants
- splice
- Prior art date
Links
- 101150017002 CD44 gene Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92970607P | 2007-07-10 | 2007-07-10 | |
| PCT/IB2008/052786 WO2009007934A2 (en) | 2007-07-10 | 2008-07-10 | Cd44 splice variants in neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL203130A true IL203130A (en) | 2014-07-31 |
Family
ID=40229192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL203130A IL203130A (en) | 2007-07-10 | 2010-01-04 | Variants of 44 cd splicing products for the diagnosis and treatment of neurodegenerative diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9018180B2 (OSRAM) |
| EP (1) | EP2167692B1 (OSRAM) |
| JP (1) | JP2010532989A (OSRAM) |
| KR (1) | KR20100044793A (OSRAM) |
| CN (1) | CN101821407B (OSRAM) |
| AU (1) | AU2008273713B2 (OSRAM) |
| BR (1) | BRPI0814685A2 (OSRAM) |
| CA (1) | CA2692861A1 (OSRAM) |
| EA (1) | EA201070108A1 (OSRAM) |
| ES (1) | ES2423182T3 (OSRAM) |
| IL (1) | IL203130A (OSRAM) |
| MX (1) | MX2010000236A (OSRAM) |
| NZ (1) | NZ582390A (OSRAM) |
| WO (1) | WO2009007934A2 (OSRAM) |
| ZA (1) | ZA201000083B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945869B (zh) | 2007-12-19 | 2014-06-18 | 癌症研究技术有限公司 | 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途 |
| US8815896B2 (en) | 2010-02-01 | 2014-08-26 | The Institute Of Cancer Research: Royal Cancer Hospital | 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| BR112013024323A2 (pt) * | 2011-03-24 | 2017-06-13 | Neurim Pharmaceuticals ( 1991 ) Ltd | peptídeos neuroprotetores |
| US9399779B2 (en) * | 2011-06-08 | 2016-07-26 | The Corporation Of Mercer University | Alternative splicing constructs and methods of use |
| CN104277092B (zh) * | 2013-07-12 | 2017-10-31 | 天津医科大学 | 用于预防和/或治疗老年性痴呆的β片层阻断肽 |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US10400009B2 (en) | 2014-09-04 | 2019-09-03 | Tianjin Medical University | β-sheet breaker peptide used for preventing and/or treating alzheimer's disease |
| CN107815438A (zh) * | 2017-08-02 | 2018-03-20 | 清华大学 | 重组细胞、筛选l型钙通道调节剂的方法、试剂在制备药物中的用途和药物组合物 |
| CN117377777A (zh) | 2021-05-11 | 2024-01-09 | 纽瑞姆制药（1991）有限公司 | 诊断和治疗具有2号染色体2:107,510,000-107,540,000基因座单核苷酸多态性受试者的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990299A (en) * | 1995-08-14 | 1999-11-23 | Icn Pharmaceuticals, Inc. | Control of CD44 gene expression for therapeutic use |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6150162A (en) | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
| IL133647A0 (en) * | 1999-06-08 | 2001-04-30 | Yissum Res Dev Co | Novel cd44 variant |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| WO2002076510A1 (en) | 2001-03-23 | 2002-10-03 | Agy Therapeutics | Use of biomolecular targets in the treatment and visualization of brain tumors |
| WO2002097044A2 (en) | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| US7833779B2 (en) * | 2001-07-25 | 2010-11-16 | Jivan Biologies Inc. | Methods and systems for polynucleotide detection |
| JP2007508810A (ja) * | 2003-09-30 | 2007-04-12 | エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホトランスフェラーゼの神経変性疾患に関する診断的および治療的使用 |
| JP2008546379A (ja) * | 2005-06-16 | 2008-12-25 | エボテツク・ニユーロサイエンシーズ・ゲー・エム・ベー・ハー | 神経変性疾患のための診断および治療の標的ａｄａｒｂ２タンパク質 |
-
2008
- 2008-07-10 MX MX2010000236A patent/MX2010000236A/es active IP Right Grant
- 2008-07-10 AU AU2008273713A patent/AU2008273713B2/en active Active
- 2008-07-10 US US12/668,563 patent/US9018180B2/en active Active
- 2008-07-10 ES ES08776569T patent/ES2423182T3/es active Active
- 2008-07-10 NZ NZ582390A patent/NZ582390A/en not_active IP Right Cessation
- 2008-07-10 BR BRPI0814685A patent/BRPI0814685A2/pt not_active IP Right Cessation
- 2008-07-10 EA EA201070108A patent/EA201070108A1/ru unknown
- 2008-07-10 WO PCT/IB2008/052786 patent/WO2009007934A2/en not_active Ceased
- 2008-07-10 CN CN2008801049431A patent/CN101821407B/zh active Active
- 2008-07-10 KR KR1020107001642A patent/KR20100044793A/ko not_active Ceased
- 2008-07-10 JP JP2010515648A patent/JP2010532989A/ja active Pending
- 2008-07-10 EP EP08776569.9A patent/EP2167692B1/en active Active
- 2008-07-10 CA CA 2692861 patent/CA2692861A1/en not_active Abandoned
-
2010
- 2010-01-04 IL IL203130A patent/IL203130A/en not_active IP Right Cessation
- 2010-01-05 ZA ZA2010/00083A patent/ZA201000083B/en unknown
-
2015
- 2015-03-27 US US14/671,281 patent/US9416166B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201000083B (en) | 2011-03-30 |
| CN101821407B (zh) | 2013-09-18 |
| US20150266940A1 (en) | 2015-09-24 |
| CN101821407A (zh) | 2010-09-01 |
| MX2010000236A (es) | 2010-06-02 |
| EP2167692A2 (en) | 2010-03-31 |
| BRPI0814685A2 (pt) | 2019-09-24 |
| US9416166B2 (en) | 2016-08-16 |
| HK1145856A1 (en) | 2011-05-06 |
| WO2009007934A3 (en) | 2009-05-07 |
| JP2010532989A (ja) | 2010-10-21 |
| EA201070108A1 (ru) | 2010-06-30 |
| NZ582390A (en) | 2012-05-25 |
| ES2423182T3 (es) | 2013-09-18 |
| CA2692861A1 (en) | 2009-01-15 |
| KR20100044793A (ko) | 2010-04-30 |
| US20110172286A1 (en) | 2011-07-14 |
| AU2008273713A1 (en) | 2009-01-15 |
| AU2008273713B2 (en) | 2014-07-03 |
| US9018180B2 (en) | 2015-04-28 |
| WO2009007934A2 (en) | 2009-01-15 |
| EP2167692B1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL203130A (en) | Variants of 44 cd splicing products for the diagnosis and treatment of neurodegenerative diseases | |
| PT2614832T (pt) | Diagnóstico de pré-eclâmpsia | |
| SG10201609507TA (en) | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions | |
| IL190733A0 (en) | Methods and compositions for use in treatment of patients with autoantibody positive diseases | |
| SI2104682T1 (sl) | Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni | |
| PT2291394T (pt) | Proteínas de fusão e seus usos no diagnóstico e tratamento de leishmaniose | |
| EP2646055A4 (en) | COPPER-FREE IN VIVO CLICK CHEMISTRY FOR THE DISPOSAL OF THERAPY AND / OR DIAGNOSTIC PRODUCTS | |
| EP2051732A4 (en) | DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR | |
| PL2148667T3 (pl) | Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu | |
| ZA201100446B (en) | Therapeutic use of specific ligand in msrv associated diseases | |
| GB0714447D0 (en) | Cannabidiol for use in the treatment of neurodegenerative conditions | |
| IL213703A0 (en) | Compounds and methods for the treatment of pain and other diseases | |
| GB2465907B (en) | VHZ for diagnosis and treatment of cancer | |
| GB0908868D0 (en) | Depsipeptide and their therapeutic use | |
| GB0608647D0 (en) | Methods of diagnosis and treatment | |
| IL216717A0 (en) | USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES | |
| IL201880A0 (en) | Klotho protein and related compounds for the treatment and diagnosis of cancer | |
| GB0716577D0 (en) | Treatment and prevention of neurodegenerative diseases | |
| AU2008906524A0 (en) | Diagnostic and therapeutic agents | |
| AU2009900783A0 (en) | Therapeutic and diagnostic agents | |
| GB0605738D0 (en) | Novel diagnostic and therapeutic methods | |
| GB0626034D0 (en) | Autism treatment and diagnosis | |
| AU2009902615A0 (en) | Therapeutic and diagnostic molecules | |
| IL190531A0 (en) | Cannabinoid for the treatment of neuronal damage in diabetic patients | |
| GB0610046D0 (en) | Materials and methods relating to the diagnosis and treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |